CVS Group plc

OTCPK:CVSG.F Stock Report

Market Cap: US$748.2m

CVS Group Valuation

Is CVSG.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CVSG.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CVSG.F ($11.84) is trading below our estimate of fair value ($26.38)

Significantly Below Fair Value: CVSG.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CVSG.F?

Key metric: As CVSG.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CVSG.F. This is calculated by dividing CVSG.F's market cap by their current earnings.
What is CVSG.F's PE Ratio?
PE Ratio22.5x
EarningsUK£26.20m
Market CapUK£589.70m

Price to Earnings Ratio vs Peers

How does CVSG.F's PE Ratio compare to its peers?

The above table shows the PE ratio for CVSG.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.2x
USPH U.S. Physical Therapy
103.9x29.4%US$1.5b
NHC National HealthCare
15.5xn/aUS$1.9b
ARDT Ardent Health Partners
24.7x38.5%US$2.3b
CON Concentra Group Holdings Parent
16.5x4.0%US$2.9b
CVSG.F CVS Group
22.5x15.5%US$589.7m

Price-To-Earnings vs Peers: CVSG.F is good value based on its Price-To-Earnings Ratio (22.5x) compared to the peer average (40.2x).

Price to Earnings Ratio vs Industry

How does CVSG.F's PE Ratio compare vs other companies in the US Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NEUE NeueHealth
1.4xn/aUS$39.39m
IDXG Interpace Biosciences
2.8xn/aUS$13.61m
FZMD Fuse Medical
1.5xn/aUS$5.79m
No more companies available in this PE range
CVSG.F 22.5xIndustry Avg. 24.4xNo. of Companies11PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CVSG.F is good value based on its Price-To-Earnings Ratio (22.5x) compared to the US Healthcare industry average (24.4x).

Price to Earnings Ratio vs Fair Ratio

What is CVSG.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CVSG.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CVSG.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CVSG.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$19.12
0%
30.2%US$30.07US$11.93n/a8
Nov ’25US$12.92
US$20.62
+59.7%
25.7%US$30.62US$12.83n/a8
Oct ’25US$14.05
US$21.47
+52.8%
25.2%US$31.79US$13.79n/a8
Sep ’25n/a
US$20.31
0%
23.8%US$30.08US$13.05n/a9
Aug ’25n/a
US$20.53
0%
24.1%US$30.46US$12.85n/a9
Jul ’25n/a
US$20.19
0%
25.6%US$29.96US$12.64n/a8
Jun ’25n/a
US$20.99
0%
25.1%US$30.13US$12.71n/a9
May ’25n/a
US$23.20
0%
28.5%US$34.28US$12.46n/a10
Apr ’25n/a
US$24.38
0%
24.2%US$35.03US$15.29n/a10
Mar ’25n/a
US$28.45
0%
18.4%US$34.94US$19.44n/a10
Feb ’25n/a
US$28.45
0%
18.4%US$34.94US$19.44n/a10
Jan ’25n/a
US$27.89
0%
18.9%US$34.56US$19.23n/a10
Dec ’24n/a
US$28.41
0%
15.9%US$33.94US$21.05n/a9
Nov ’24n/a
US$27.60
0%
15.6%US$33.80US$20.96US$12.928
Oct ’24n/a
US$27.60
0%
15.6%US$33.80US$20.96US$14.058
Sep ’24n/a
US$30.88
0%
9.9%US$34.98US$26.90n/a9
Aug ’24n/a
US$31.11
0%
9.5%US$35.16US$27.04n/a9
Jul ’24n/a
US$28.10
0%
11.0%US$32.53US$22.95n/a8
Jun ’24n/a
US$28.10
0%
11.0%US$32.53US$22.95n/a8
May ’24n/a
US$28.10
0%
11.0%US$32.53US$22.95n/a8
Apr ’24US$23.86
US$28.10
+17.8%
11.0%US$32.53US$22.95n/a8
Mar ’24n/a
US$28.40
0%
10.8%US$32.84US$24.60n/a7
Feb ’24n/a
US$29.45
0%
11.1%US$34.14US$25.57n/a7
Jan ’24n/a
US$26.04
0%
10.8%US$31.21US$22.36n/a6
Dec ’23US$23.80
US$26.04
+9.4%
10.8%US$31.21US$22.36n/a6
Nov ’23n/a
US$26.34
0%
10.8%US$31.58US$22.62n/a6

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.75

7D

0.05%

1Y

-16.6%

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.27

7D

-0.3%

1Y

22.3%

Sensus Healthcare

US$141.0m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

SRTS

US$8.60

7D

-3.3%

1Y

253.9%